Sharps Technology, Inc.

STSS

US82003F1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
0.382 ^USD	-20.08%		+78.25%	-8.15%

05-30	Sharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S	CI
05-14	Sharps Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Sharps Technology, Inc.

Sharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S	05-30	CI
Sharps Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Sharps Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia	02-21	CI
Sharps Technology Planning to Collaborate with Roncadelle to Support Global Distribution and Sales of High Quality, Innovative, Safer Drug Delivery Systems	02-16	CI
Sharps Technology Signs LoI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems	01-18	CI
Sharps Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sharps Technology, Inc. announced that it has received $2.827853 million in funding	28/09/23	CI
Sharps Technology Launches $5.6 Million Registered Direct Offering	27/09/23	MT
Sharps Technology, Inc. announced a financing transaction	26/09/23	CI
Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals	26/09/23	CI
Sharps Technology, Inc. entered into a definitive agreement to acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility from Nephron Pharmaceuticals Corporation for $50 million.	25/09/23	CI
Sharps Technology Files $200 Million Mixed Shelf	23/08/23	MT
Sharps Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Sharps Technology Appoints Ben Scheu as Senior Director of Sales	12/07/23	CI
Sharps Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Top Premarket Gainers	10/05/23	MT
Sharps Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Sharps Technology, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Sharps Technology, Inc. announced that it has received $3.8 million in funding	05/02/23	CI
Sharps Technology To Raise $3.8 Million Through At-The-Market Private Placement	01/02/23	MT
Sharps Technology, Inc. announced that it expects to receive $3.8 million in funding	31/01/23	CI
Sharps Technology, Inc. Ships First Containers of Safety Syringes to Nephron Pharmaceuticals for Commercialization	31/01/23	CI
Sharps Technology Inc. to Introduces New Specialized Prefillable Syringe Systems in 2023	10/01/23	CI
Sharps Technology, Inc Begins Manufacturing At Its Hungary Facility for the Company's Innovative Syringe Products	20/12/22	CI

Sharps Technology, Inc. is a medical device and pharmaceutical packaging company. The Company is engaged in offering patented smart-safety syringe products to the healthcare industry. The Company's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. It Sharps Securegard and Sologard, and Roncadelle SafeR safety syringe product lines incorporate both active and passive safety features and have been designed to address the three primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. It also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. It has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.

Sector

Medical Equipment, Supplies & Distribution

More about the company

	1st Jan change	Capi.
SHARPS TECHNOLOGY, INC.	-8.15%	5.99M
ABBOTT LABORATORIES	-7.16%	178B
MEDTRONIC PLC	-1.23%	107B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.23B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+8.14%	42.5B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.76%	29.99B
TERUMO CORPORATION	+15.53%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B